Humapent (Cyclopentolate Hydrochloride)

Humapent is indicated for several ophthalmic procedures that require controlled dilation of the pupil and temporary loss of accommodation.

• Pupil dilation for routine ophthalmic examinations such as fundoscopy or slit‑lamp evaluation.
• Cycloplegia to facilitate accurate refractive measurements in children or patients with accommodative disorders.
• Adjunctive therapy in the management of anterior uveitis to improve visualization of intra‑ocular structures.
• Pre‑operative preparation for intraocular surgery where a stable, dilated pupil is needed.
• Diagnostic testing that involves assessment of the posterior segment, such as retinal photography.

• Cyclopentolate hydrochloride acts as a reversible, non‑selective antagonist of muscarinic acetylcholine receptors (M1‑M5) located in the iris sphincter muscle and the ciliary body. By blocking these receptors, it prevents acetylcholine‑mediated contraction, leading to relaxation of the sphincter (mydriasis) and inhibition of the ciliary muscle’s accommodative ability (cycloplegia). The effect is temporary and wears off as the drug is metabolized and cleared from ocular tissues.

Adverse reactions to Humapent are generally mild and transient, but rare serious events have been reported.

Common

• Transient stinging or burning sensation at the ocular surface that usually resolves within a few minutes after instillation.
• Temporary blurred vision caused by the dilated pupil, which typically improves as the drug effect diminishes.
• Mild photophobia, especially in bright indoor lighting, that lessens as the pupil returns to normal size.
• Slight, often asymptomatic, rise in intra‑ocular pressure that should be monitored in patients with glaucoma risk factors.

Serious

• Acute angle‑closure glaucoma, a vision‑threatening emergency that can occur if the dilated pupil blocks aqueous outflow.
• Systemic anticholinergic toxicity, manifesting as dry mouth, rapid heart rate, urinary retention, or confusion, particularly after excessive ocular absorption or concurrent systemic anticholinergics.

Before using Humapent, clinicians should evaluate patient history and ocular conditions to minimize risk.

• Assess for narrow anterior chamber angles or prior angle‑closure glaucoma, as dilation may trigger an attack.
• Confirm no hypersensitivity to cyclopentolate or related anticholinergics.
• Exercise caution in patients with uncontrolled diabetes, cardiovascular disease, or hyperthyroidism.
• Avoid use in infants under six months unless specifically indicated.
• Check for concurrent mydriatics or topical steroids that could affect pupil response.
• Record baseline intra‑ocular pressure and monitor for significant changes post‑administration.

Humapent may interact with other ophthalmic or systemic agents that influence pupil size, intra‑ocular pressure, or anticholinergic load.

Avoid

• Concurrent use with other potent mydriatics (e.g., phenylephrine) that may cause excessive dilation and increase risk of angle‑closure glaucoma.
• Systemic anticholinergic drugs (e.g., atropine, antihistamines) that could amplify anticholinergic side effects.

Use with caution

• Topical ocular steroids, which can raise intra‑ocular pressure and may mask pressure changes after cyclopentolate.
• Beta‑blocker eye drops, as combined effects on pupil dynamics may be unpredictable.
• Patients on systemic medications that affect the autonomic nervous system (e.g., tricyclic antidepressants), requiring closer monitoring.